Shilpa Medicare unit settles Rs 9 Cr dispute against Rs 20.13 Cr claim

Shilpa Biologicals, a material subsidiary of Shilpa Medicare , has settled a commercial dispute with Sartorius Stedim India for Rs 9 Cr. The settlement agreement was executed on June 23, 2026, before the Hon'ble XI Addl. City Civil and Sessions Court, Commercial Court, Bengaluru, concluding legal proceedings in Commercial O.S. No. 153/2024.

Sartorius Stedim India had initially alleged a claim of Rs 20.13 Cr plus applicable interest. Following negotiations, the parties agreed to a reduced settlement amount of Rs 9 Cr, which was paid by Shilpa Biologicals. The company stated that the financial impact of this settlement is limited to the payment amount.

Details of the Settlement

The following table outlines the key particulars of the settlement and the judicial proceedings:

Sr. No.	Particulars	Details
1.	Name of the Authority	Hon'ble XI Addl. City Civil and Sessions Court, Commercial Court, Bengaluru
2.	Nature and details of action passed	Agreement signed by both the parties towards settlement amount Rs 9,00,00,000 before the court.
3.	Date of agreement	23 June 2026
4.	Details of violation(s)	NA
5.	Impact on financial or operational activities	The impact will be limited to the settlement amount.

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.39%	-0.14%	+16.59%	+79.30%	-33.85%	+107.70%

Shilpa Biologicals Pvt Ltd, a material subsidiary of Shilpa Medicare , has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility in Dharwad. The facility is designed to meet global regulatory approval standards including US FDA and EMA requirements. It is fully operational, with GMP qualification protocols now actively underway, placing the company on a path to commercial readiness.

Strategic Expansion and Capabilities

The commissioning marks a significant evolution of Shilpa Medicare's over 25 years of expertise in highly potent compound manufacturing. The company has established a robust High Potency API (HPAPI) platform, which demands exacting standards of containment and safety engineering. With this new facility, Shilpa Medicare becomes one of the very few companies in India to offer fully integrated, end-to-end ADC Drug Substance development and manufacturing.

Integrated Service Offering

The new facility enables the company to provide a comprehensive range of services, encompassing payload synthesis, linker development and manufacturing, monoclonal antibody production, ADC conjugation, and purification of GMP-scale Drug Substance. This positions Shilpa Medicare as a cost-competitive Contract Development and Manufacturing Organization (CDMO) partner for global pharmaceutical and biotech companies.

Feature	Description
Facility Type	Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility
Status	Fully Operational; GMP qualification protocols underway
Regulatory Standards	US FDA, EMA, and other major health authority requirements
Key Capabilities	Payload synthesis, linker development, mAb production, conjugation, purification

Management Commentary

Sridevi Khambhampaty, CEO of Shilpa Biologicals Pvt Ltd, highlighted that the manufacturing of highly potent compounds has been a core pillar of the company's identity. She stated that the ADC Drug Substance facility adds a sophisticated dimension to the group's capabilities, offering global partners an integrated facility built on high potency manufacturing excellence.

Vishnukant Bhutada, Managing Director of Shilpa Medicare Ltd, noted that India now possesses the infrastructure to be a trusted partner in global ADC Drug Substance manufacturing. He emphasized that the company's 25-year legacy in high potency manufacturing provides a distinct advantage, allowing it to provide a comprehensive one-stop solution to oncology innovators. The commissioning reinforces Shilpa Medicare's commitment to high-value biologics and innovation-driven GMP manufacturing, representing a decisive step in its strategy to become a globally relevant CDMO partner for advanced oncology ADC Drug Substance manufacturing.